This study, called RECLAIM, is looking at how well varenicline (Chantix) works compared to a placebo (an inactive substance) for people who use both tobacco and cannabis. Varenicline is not currently approved by the FDA for treating both at the same time. All participants will also receive counseling and access to online tools to help them quit cigarettes and reduce or quit cannabis. To join, you must be 18 or older, smoke at least 5 cigarettes daily most days, want to quit tobacco, and want to reduce or quit cannabis. You'll also need a positive test for nicotine and cannabis before starting. The main goal is to see if participants can stop smoking cigarettes during the last 7 days of the 12-week treatment. This study is being done remotely, so no in-person visits are needed. The current recruitment status is unclear.

Study design

This study plans to enroll 200 participants who will be randomly assigned to receive either varenicline or a placebo. It is an interventional study, but the phase is not specified.

What's involved

Participants will take varenicline or placebo daily, following a specific dose schedule. They will also receive weekly skills-based counseling and have access to online treatment modules for 12 weeks.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome of cigarette abstinence is measured at the final 7 days of treatment (Week 11 through Week 12).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.